Leucine-rich repeat kinase 2, ABclonal, A17253

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human Leucine-rich repeat kinase 2 and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 13 commercial research antibodies against human Leucine-rich repeat kinase 2 encoded by LRRK2.

The collection of antibodies was tested using A549 WT and LRRK2 KO cells in the applications WB (WT and KO cell lysates/25 µg protein), IP (WT cell lysate) and IF (WT and KO cells) according to YCharOS standard protocols (see reference).

In WB (1:500 ab dilution) A17253 detected a band of appr. 245 kDa in both genotypes, furthermore more intense bands of lower molecular weight were observed in both genotypes as well. A band was also detected following IP (2 µg Ab used). This band was more intense than the corresponding band in input extract (4% of starting material). A band was detected in immunodepleted extract (4% of total unbound fraction), showing that the antibody does not completely deplete the antigen from the cell lysate. In IF (1:200 ab dilution), ) comparable staining intensities were observed in both KO and WT cells.

We highly encourage other scientists to share their observations.